Astra Aktiebolag

Astrazeneca Ab

Aktiebolaget Draco

Aktiebolaget Astra

Jan W Trofast

Edib Jakupovic

Bengt I Axelsson

John Kelshaw Conway

Allan Dagsland

Bror Arne Thalen

Volker Tiedemann

Jan Andersson

Stefan Friess

Uwe Rollwage

Harald Heckenmueller

Paul H Andersson

Per T Andersson

Hans Strid

Eva A Trofast

Per Lennart Lindberg

Ralph Lennart Brattsand

Carl-Axel Wilhelm Bauer

Jordi Serra-Carreras

Joan Pi&ntilde;as-Mass&oacute;

Christer Carl Carling

Carl Magnus Dahlback

Lars-Erik Briggner

Katarina Bystrom

Katarina L Mansson

Katarina U Bystrom

Leif A Kallstrom

The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.

Use for budesonide and formoterol

A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means () for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means ().

Inhaler with powder dislodging member

Inhalation device

A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means ( ) for providing a dose of powder to the flow path for entertainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means ( ).

The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H , K -ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.

Use of an H&plus;, K&plus;-ATPase inhibitor in the treatment of Widal's Syndrome

The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H ,K -ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.

Use of an H&plus;, K&plus;-atpase inhibitor in the treatment of nasal polyps

A dry powder composition comprising one more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.

Formulation for inhalation

A process for producing a pharmaceutical powder for inhalation comprising crystalline particles of an inhalation compound, comprising dissolving an inhalation compound in a solvent; and introducing the solution containing the inhalation compound in droplet form or as a jet stream into an anti-solvent which is miscible with the solvent and which is under agitation.

Process for the preparation of respirable particles

A dry powder composition comprising formoterol and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.

A dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.

A dry powder composition comprising budesonide and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.

A dry powder composition comprising terbutaline sulphate and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.

Effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

Growing community of inventors

Lund, Sweden

Jan W Trofast